S100A12 and Soluble Receptor for Advanced Glycation End Products Levels During Human Severe Sepsis
Ahmed Achouiti(University of Amsterdam), Marieke A. D. van Zoelen(Long Island University), J. W. Olivier van Till(Astellas Pharma (Netherlands)), Thierry Dugernier(Clinique Saint Pierre), Tom van der Poll(Amsterdam Neuroscience), Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Johannes Roth(University of Münster), Xavier Wittebole(Cliniques Universitaires Saint-Luc), Marja A. Boermeester(Amsterdam University Medical Centers), Dirk Föll(University Hospital Münster), Thomas Vogl(Goethe University Frankfurt)
Cited by 35
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure
|New England Journal of Medicine|2015|2.4k
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
|Clinical Infectious Diseases|2014|1.1k